Figure 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
<p>Best change from baseline in sum of target lesions (investigator assessment) in the dose-expansion phase for the NSCLC cohorts (<b>A</b>, <b>C</b>, and <b>E</b>) and baseline tumor H-score levels for AXL positivity by investigator-assessed confirmed best...
Saved in:
Similar Items
-
Figure 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
by: Kristoffer Staal Rohrberg (15009138)
Published: (2025) -
Figure S1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
by: Kristoffer Staal Rohrberg (15009138)
Published: (2025) -
Figure S2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
by: Kristoffer Staal Rohrberg (15009138)
Published: (2025) -
Figure S3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
by: Kristoffer Staal Rohrberg (15009138)
Published: (2025) -
Table 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
by: Kristoffer Staal Rohrberg (15009138)
Published: (2025)